Cargando…
Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors
BACKGROUND: Malignant peripheral nerve sheath tumors (MPNST) are rare highly aggressive sarcomas that affect 8-13% of people with neurofibromatosis type 1. The prognosis for patients with MPNST is very poor. Despite TOP2A overexpression in these tumors, doxorubicin resistance is common, and the mech...
Autores principales: | Peacock, Jacqueline D, Cherba, David, Kampfschulte, Kevin, Smith, Mallory K, Monks, Noel R, Webb, Craig P, Steensma, Matthew |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3848568/ https://www.ncbi.nlm.nih.gov/pubmed/24040940 http://dx.doi.org/10.1186/1479-5876-11-213 |
Ejemplares similares
-
Malignant Peripheral Nerve Sheath Tumour of the Maxilla
por: Sahai, Puja, et al.
Publicado: (2014) -
CT of malignant peripheral nerve sheath tumor
por: Lugo-Fagundo, Elias, et al.
Publicado: (2022) -
Malignant peripheral nerve sheath tumor: A rare malignancy
por: Sharma, Sheetal, et al.
Publicado: (2020) -
Tumor targeted delivery of doxorubicin in malignant peripheral nerve sheath tumors
por: Madhankumar, A. B., et al.
Publicado: (2018) -
Malignant peripheral nerve sheath tumours in inherited disease
por: Evans, D Gareth R, et al.
Publicado: (2012)